Subscribe
10 September 2025NewsAmericasMercedes Meyer and Brandon Phemester

Killing the golden goose of US drug innovation (Part I)

In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
The flaw that landed Sanofi a win in the rare disease space
4 September 2025   The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.
Biotechnology
An update on patenting in Ukraine, Russia and Eurasia
2 September 2025   Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Europe
The flaw that landed Sanofi a win in the rare disease space
4 September 2025   The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.
Biotechnology
An update on patenting in Ukraine, Russia and Eurasia
2 September 2025   Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

More on this story

Europe
The flaw that landed Sanofi a win in the rare disease space
4 September 2025   The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.
Biotechnology
An update on patenting in Ukraine, Russia and Eurasia
2 September 2025   Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

More features

Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space